Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9

Whitehawk Therapeutics

Whitehawk Therapeutics

WHWK

0.00

Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Outperform rating and announces Price Target of $9.